TCDA Tricida Inc.

+0.38  (+1%)
Previous Close 33.05
Open 33.07
Price To Book 10.22
Market Cap 1,642,758,792
Shares 49,140,257
Volume 21,085
Short Ratio
Av. Daily Volume 258,357

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 efficacy trial met endpoints June 2018. 12-month registration stability data due mid-2019. TRCA-301E data also met primary endpoint.
TRC 101
Chronic kidney disease

Latest News

  1. Does Tricida's (NASDAQ:TCDA) Share Price Gain of 35% Match Its Business Performance?
  2. Should Tricida (NASDAQ:TCDA) Be Disappointed With Their 35% Profit?
  3. Here’s What Hedge Funds Think About Tricida, Inc. (TCDA)
  4. Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
  5. featured highlights include: Stifel, Napco, Tricida and Under Armour
  6. 4 Stocks Set to Pop on New Analyst Coverage
  7. Tricida to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  8. Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript
  9. Tricida Announces First Quarter 2019 Financial Results
  10. Did Hedge Funds Drop The Ball On Tricida, Inc. (TCDA) ?
  11. Tricida to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, May 8, 2019
  12. What Kind Of Shareholder Owns Most Tricida, Inc. (NASDAQ:TCDA) Stock?
  13. Here's What Drove Tricida 67% Higher in March
  14. Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  15. The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
  16. Tricida Announces Pricing of Public Offering of Common Stock
  17. Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
  18. Why MAG Silver, comScore, and Tricida Slumped Today
  19. Tricida Announces Proposed Public Offering of Common Stock
  20. Will Tricida Continue to Surge Higher?